Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice

Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 Charlton, 2011, Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States, Gastroenterology, 141, 1249, 10.1053/j.gastro.2011.06.061 Ratziu, 2015, Current efforts and trends in the treatment of NASH, J Hepatol, 62, S65, 10.1016/j.jhep.2015.02.041 Rotman, 2017, Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease, Gut, 66, 180, 10.1136/gutjnl-2016-312431 Ratziu, 2016, Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, 150, 1147, 10.1053/j.gastro.2016.01.038 Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4 Loomba, 2017, The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial, Hepatology Wang, 2012, MicroRNAs in liver disease, Gastroenterology, 142, 1431, 10.1053/j.gastro.2012.04.007 Szabo, 2012, MicroRNA silencing and the development of novel therapies for liver disease, J Hepatol, 57, 462, 10.1016/j.jhep.2012.01.030 Rupaimoole, 2017, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases, Nat Rev Drug Discov, 16, 203, 10.1038/nrd.2016.246 Esau, 2006, miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting, Cell Metab, 3, 87, 10.1016/j.cmet.2006.01.005 Jopling, 2005, Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA, Science, 309, 1577, 10.1126/science.1113329 Janssen, 2013, Treatment of HCV infection by targeting microRNA, N Engl J Med, 368, 1685, 10.1056/NEJMoa1209026 Trajkovski, 2011, MicroRNAs 103 and 107 regulate insulin sensitivity, Nature, 474, 649, 10.1038/nature10112 Loyer, 2016, Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression, Gut, 65, 1882, 10.1136/gutjnl-2014-308883 Pineau, 2011, miR-221 overexpression contributes to liver tumorigenesis, Proc Natl Acad Sci U S A, 107, 264, 10.1073/pnas.0907904107 Park, 2011, miR-221 silencing blocks hepatocellular carcinoma and promotes survival, Cancer Res, 71, 7608, 10.1158/0008-5472.CAN-11-1144 Callegari, 2012, Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model, Hepatology, 56, 1025, 10.1002/hep.25747 Ogawa, 2012, MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis, Gut, 61, 1600, 10.1136/gutjnl-2011-300717 Shen, 2014, MicroRNA-222 modulates liver fibrosis in a murine model of biliary atresia, Biochem Biophys Res Commun, 446, 155, 10.1016/j.bbrc.2014.02.065 Cao, 2009, Nuclear-cytoplasmic shuttling of menin regulates nuclear translocation of beta-catenin, Mol Cell Biol, 29, 5477, 10.1128/MCB.00335-09 Kim, 2015, HISAT: a fast spliced aligner with low memory requirements, Nat Methods, 12, 357, 10.1038/nmeth.3317 Langmead, 2009, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol, 10, R25, 10.1186/gb-2009-10-3-r25 Li, 2011, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome, BMC Bioinformatics, 12, 323, 10.1186/1471-2105-12-323 Federici, 2005, Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha, J Clin Invest, 115, 3494, 10.1172/JCI26052 Mohammed, 2004, Abnormal TNF activity in Timp3−/− mice leads to chronic hepatic inflammation and failure of liver regeneration, Nat Genet, 36, 969, 10.1038/ng1413 Casagrande, 2017, Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma, Sci Rep, 7, 6747, 10.1038/s41598-017-06439-x Menghini, 2012, TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice, Diabetes, 61, 454, 10.2337/db11-0613 Fornari, 2008, MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma, Oncogene, 27, 5651, 10.1038/onc.2008.178 le Sage, 2007, Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation, EMBO J, 26, 3699, 10.1038/sj.emboj.7601790 Garofalo, 2009, miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation, Cancer Cell, 16, 498, 10.1016/j.ccr.2009.10.014 Sun, 2009, The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines, Cancer Res, 69, 3356, 10.1158/0008-5472.CAN-08-4112 Di Leva, 2010, MicroRNA cluster 221–222 and estrogen receptor alpha interactions in breast cancer, J Natl Cancer Inst, 102, 706, 10.1093/jnci/djq102 Frenquelli, 2010, MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27, Blood, 115, 10.1182/blood-2009-11-254656 Zhang, 2010, MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma, Mol Cancer, 9, 229, 10.1186/1476-4598-9-229 Quintavalle, 2012, miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ, Oncogene, 31, 858, 10.1038/onc.2011.280 Liu, 2014, A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells, Gastroenterology, 147, 847, 10.1053/j.gastro.2014.06.006 Gullà, 2016, A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells, Clin Cancer Res, 22, 1222, 10.1158/1078-0432.CCR-15-0489 Gallo Cantafio, 2016, Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates, Mol Ther Nucleic Acids, 5, e326, 10.1038/mtna.2016.36 Ben Sahra, 2011, Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1, Cancer Res, 71, 4366, 10.1158/0008-5472.CAN-10-1769 Williamson, 2015, Aberrant REDD1-mTORC1 responses to insulin in skeletal muscle from Type 2 diabetics, Am J Physiol Regul Integr Comp Physiol, 309, R855, 10.1152/ajpregu.00285.2015 Pastor, 2017, Implication of REDD1 in the activation of inflammatory pathways, Sci Rep, 7, 7023, 10.1038/s41598-017-07182-z Kassiri, 2009, Loss of TIMP3 enhances interstitial nephritis and fibrosis, J Am Soc Nephrol, 20, 1223, 10.1681/ASN.2008050492 Fan, 2014, Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction, Cardiovasc Res, 103, 268, 10.1093/cvr/cvu072 Menghini, 2009, Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice, Gastroenterology, 136, 663, 10.1053/j.gastro.2008.10.079 Jiang, 2013, Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice, Hepatology, 58, 1339, 10.1002/hep.26491